Stewart Dolin
Professional Services |
Law Firms
10 South Wacker Drive, Chicago, IL 60606
Recent News About Stewart Dolin
View More
-
SCOTUS ruling changed "approach" to drug labeling questions, plaintiffs said. GSK says the change wasn't "extraordinary" enough and would open "floodgates" to attempts at lawsuit "do-overs."
-
In the wake of the U.S. Supreme Court’s recent refusal to hear her case, the widow of a Chicago man, who killed himself after allegedly taking the generic form of the antidepressant Paxil, is trying to have a federal district judge restore her $3 million verdict against drugmaker GSK, because the company allegedly didn’t push federal regulators to revise the drug’s warning label.
-
The widow of a lawyer who took his own life, allegedly after taking the generic equivalent of widely prescribed antidepressant drug, Paxil, will not get a chance to undo a federal appeals court’s decision to toss out a federal jury’s findings that GSK, the maker of Paxil, owes her $3 million because it allegedly didn’t push federal regulators hard enough to revise the drug’s warning label.
-
A federal appeals court in Chicago could be tasked with taking another look at its previous decision undoing a jury verdict ordering drug maker GSK to pay $3 million to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of a widely prescribed antidepressant drug.
-
The U.S. Supreme Court is tackling the question of whether drug companies can be sued for not making their warning labels strong enough, even though the FDA controls the labels. But whether a forthcoming Supreme Court decision will affect a decision denying a $3 million judgment to the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of Paxil remains unclear.
-
Asserting a Chicago federal appeals panel wrongly invalidated a jury’s verdict, attorneys for the widow of a Chicago lawyer who committed suicide after taking the generic version of the antidepressant drug Paxil, have asked the U.S. Supreme Court to throw out the appellate ruling and order more proceedings on whether pharmaceutical company GlaxoSmithKline should be made to pay for allegedly not revising their drug’s warning label to reflect an increased risk of suicide.
-
A Chicago federal appellate court has refused to reexamine its decision last month that reversed a $3 million verdict against drugmaker GlaxoSmithKline, on grounds the company was not responsible for the labeling of the generic version of its product Paxil, despite plaintiff’s urging a rehearing was needed, because she said the appeals panel set a “dangerous precedent.”
-
A federal appeals panel has tossed out a $3 million verdict vs GSK for the widow of a Chicago lawyer who committed suicide after taking the generic equivalent of GSK's drug, Paxil. The judges said the company can't be held responsible for language on the warning label when that language was controlled by the FDA.
-
The U.S. Supreme Court has decided to wade into the contentious question over whether a pharmaceutical company can be held liable for failing to warn consumers and doctors of a drug’s potential effects, potentially portending significant implications for a $3 million verdict a jury awarded to the widow of a Chicago lawyer who committed suicide in the Loop after taking the generic version of an antidepressant drug.
-
With one judge saying he found “troubling” the potential harm to patients from decreased incentives for drug makers to develop new breakthrough medications, a federal appellate panel in Chicago hashed out some of the legal questions surrounding the appeal of jury’s verdict ordering GlaxoSmithKline to pay $3 million to the widow of a Chicago lawyer who committed suicide, and whose family has accused the pharmaceutical company of failing to warn that a generic version of its drug Paxil could raise a patient’s risk of suicide.
-
As a federal appeals court in Chicago prepares to hear arguments later this month on the question of whether a drug company should bear responsibility for the effects of a generic equivalent medication they did not make or sell, pharmaceutical company GlaxoSmithKline has asked the judges to lend weight to a West Virginia Supreme Court delivered in recent days, which declared using drug warning labels to hold innovators liable for harm caused by a generic copy of their product would “sever the connection between risk and reward,” both raising prices and reducing innovation.
-
The thinking behind a Massachusetts ruling that brand-name manufacturers can he held liable for injuries suffered by patients who take generic versions of the drug those manufacturers innovate could have bearing in a case before a federal appeals court in Chicago.
-
About two weeks after a Chicago federal judge turned down its request for a new trial, pharmaceutical maker GlaxoSmithKline has formally appealed the judicial decisions the company has contended led to a jury improperly awarding $3 million to the widow of a Chicago lawyer who committed suicide by stepping in front of a train in Chicago’s Loop after taking a generic version of Paxil, an antidepressant developed by GSK.
-
Pharmaceutical maker GlaxoSmithKline will not get a chance to undo a jury’s verdict, finding it owes $3 million to the widow of a Chicago lawyer who committed suicide, allegedly after taking a generic equivalent of GSK’s anti-depressant drug, Paxil.
-
A Chicago federal jury shocked many observers by ordering drugmaker GlaxoSmithKline to pay $3 million to the widow of lawyer Stewart Dolin, who committed suicide in 2010 after taking a generic version of GSK's antidepressant Paxil. But legal observers believe the decision may have a short shelf life, as it could defy decades of case law on the concept of innovator liability.
-
Drug manufacturer GlaxoSmithKline is trying to get out from under a $3 million jury judgment, which blamed it for a Chicago lawyer’s suicide, saying a federal judge made multiple mistakes that hamstrung the manufacturer’s defense against the claim its labels failed to warn its anti-depressant drug Paxil and its generic equivalent can lead to suicide.
-
A federal jury in Chicago has ordered pharmaceutical maker GlaxoSmithKline to pay $3 million to the widow of a Chicago lawyer who committed suicide by jumping in front of a train after taking a generic version of Paxil, an antidepressant developed by GSK, finding the drugmaker should be held responsible for his death, even though it didn’t make the actual medication the lawyer had been taking for about a week before he took his life.
-
A trial continues this week in Chicago federal court over the question of how much blame should be shouldered by drugmaker GlaxoSmithKline for the death of a Chicago lawyer who committed suicide after taking a generic version of Paxil, an antidepressant developed by GSK. This week, a federal judge denied an attempt by GSK to abruptly end the weeks-long trial and secure a judgment in its favor.
-
This week, a Chicago federal court will empanel jurors to decide whether pharmaceutical maker GlaxoSmithKline should be made to pay the widow of a Chicago lawyer who committed suicide by jumping in front of a train after taking a generic version of Paxil, an antidepressant developed by GSK, because, the woman claims, the drug’s warning label, which was approved by federal regulators, did not contain enough information on suicide risk, misleading the doctor who prescribed it.
